How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nucleos-t-ide-analogue-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Nucleos(t)ide analogue therapy — Competitive Intelligence Brief

Nucleos(t)ide analogue therapy (Nucleos(t)ide analogue therapy) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleos(t)ide reverse transcriptase inhibitor / Nucleos(t)ide polymerase inhibitor. Area: Virology / Infectious Disease.

marketed Nucleos(t)ide reverse transcriptase inhibitor / Nucleos(t)ide polymerase inhibitor Viral reverse transcriptase (HIV) or viral polymerase (HBV) Virology / Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Nucleos(t)ide analogue therapy (Nucleos(t)ide analogue therapy) — Seng Gee Lim. Nucleos(t)ide analogues inhibit viral reverse transcriptase and/or polymerase, preventing viral DNA synthesis and replication.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nucleos(t)ide analogue therapy TARGET	Nucleos(t)ide analogue therapy	Seng Gee Lim	marketed	Nucleos(t)ide reverse transcriptase inhibitor / Nucleos(t)ide polymerase inhibitor	Viral reverse transcriptase (HIV) or viral polymerase (HBV)
Nucleos(t)tide analogues	Nucleos(t)tide analogues	King Abdullah International Medical Research Center	marketed	Nucleos(t)ide reverse transcriptase inhibitor / Nucleos(t)ide polymerase inhibitor	Viral reverse transcriptase; viral polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleos(t)ide reverse transcriptase inhibitor / Nucleos(t)ide polymerase inhibitor class)

King Abdullah International Medical Research Center · 1 drug in this class
Seng Gee Lim · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nucleos(t)ide analogue therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/nucleos-t-ide-analogue-therapy. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab